Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia

Background and Purpose— Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury. In part, these phenomena may be related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). Here, we used a combination of pharmacological and genetic approaches to show that tPA promotes MMP-9 levels in stroke in vivo. Methods— In the first experiment, spontaneously hypertensive rats were subjected to 3 hours of transient focal cerebral ischemia. The effects of tPA (10 mg/kg IV) on ischemic brain MMP-9 levels were assessed by zymography. In the second experiment, wild-type (WT) and tPA knockout mice were subjected to 2 hours of transient focal cerebral ischemia, and MMP-9 levels and brain edema during reperfusion were assessed. Phenotype rescue was performed by administering tPA to the tPA knockout mice. Results— In the first experiment, exogenous tPA did not change infarct size but amplified MMP-9 levels in ischemic rat brain at 24 hours. Coinfusion of the plasmin inhibitor tranexamic acid (300 mg/kg) did not ameliorate this effect, suggesting that it was independent of plasmin. In the second experiment, ischemic MMP-9 levels, infarct size, and brain edema in tPA knockouts were significantly lower than WT mice. Administration of exogenous tPA (10 mg/kg IV) did not alter infarction but reinstated the ischemic MMP-9 response back up to WT levels and correspondingly worsened edema. Conclusions— These data demonstrate that tPA upregulates brain MMP-9 levels in stroke in vivo, and suggest that combination therapies targeting MMPs may improve tPA therapy.

[1]  Karim Benchenane,et al.  Arginine 260 of the Amino-terminal Domain of NR1 Subunit Is Critical for Tissue-type Plasminogen Activator-mediated Enhancement of N-Methyl-D-aspartate Receptor Signaling* , 2004, Journal of Biological Chemistry.

[2]  K. Furie,et al.  Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke , 2004, Stroke.

[3]  S. Warach,et al.  Evidence of Reperfusion Injury, Exacerbated by Thrombolytic Therapy, in Human Focal Brain Ischemia Using a Novel Imaging Marker of Early Blood–Brain Barrier Disruption , 2004, Stroke.

[4]  Steven Warach,et al.  Early blood–brain barrier disruption in human focal brain ischemia , 2004, Annals of neurology.

[5]  D. Vivien,et al.  Equivocal roles of tissue-type plasminogen activator in stroke-induced injury , 2004, Trends in Neurosciences.

[6]  K. Bdeir,et al.  In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. , 2004, Blood.

[7]  M. Moskowitz,et al.  tPA and proteolysis in the neurovascular unit. , 2004, Stroke.

[8]  D. Lawrence,et al.  Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.

[9]  V. Wee Yong,et al.  An Adverse Role for Matrix Metalloproteinase 12 after Spinal Cord Injury in Mice , 2003, The Journal of Neuroscience.

[10]  J. Marler,et al.  Stroke--tPA and the Clinic , 2003, Science.

[11]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[12]  G. Rosenberg,et al.  Tissue inhibitor of metalloproteinases‐3 and matrix metalloproteinase‐3 regulate neuronal sensitivity to doxorubicin‐induced apoptosis , 2003, The European journal of neuroscience.

[13]  J. Koziol,et al.  Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. , 2003, Stroke.

[14]  G. D. del Zoppo,et al.  Cerebral Microvessel Responses to Focal Ischemia , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  M. Delany,et al.  Poultry Genetic Resources--Operation Rescue Needed , 2003, Science.

[16]  J. M. Wardlaw,et al.  Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke: Where Do We Go From Here? A Cumulative Meta-Analysis , 2003, Stroke.

[17]  D. Corbett,et al.  Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases , 2003, Annals of neurology.

[18]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[19]  Eng H. Lo,et al.  Neurological diseases: Mechanisms, challenges and opportunities in stroke , 2003, Nature Reviews Neuroscience.

[20]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[21]  J. Serena,et al.  Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.

[22]  E. Lo,et al.  Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats , 2002, Stroke.

[23]  Reciprocal actions of NCAM and tPA via a Ras-dependent MAPK activation in rat hippocampal neurons. , 2002, Biochemical and biophysical research communications.

[24]  G. Rosenberg Rosenberg GA. Matrix metalloproteinases in neuroinflammation. GLIA 2002;39(3):279–291. , 2002 .

[25]  P. Lapchak,et al.  Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits , 2002, Stroke.

[26]  G. Rosenberg Matrix metalloproteinases in neuroinflammation , 2002, Glia.

[27]  E. Lo,et al.  Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases , 2002, Journal of neuroscience research.

[28]  C. Siao,et al.  Tissue Plasminogen Activator Mediates Microglial Activation via Its Finger Domain through Annexin II , 2002, The Journal of Neuroscience.

[29]  G. Rosenberg,et al.  Stromelysin-1 and gelatinase A are upregulated before TNF-α in LPS-stimulated neuroinflammation , 2002, Brain Research.

[30]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats , 2002, Stroke.

[31]  G. Rosenberg,et al.  Stromelysin-1 and gelatinase A are upregulated before TNF-alpha in LPS-stimulated neuroinflammation. , 2002, Brain research.

[32]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.

[33]  S. Itohara,et al.  Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia , 2001, Neuroreport.

[34]  D. Strickland,et al.  LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.

[35]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[36]  M. Fini,et al.  Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  E. Tournier-Lasserve CACNA1A mutations , 1999, Neurology.

[38]  W. Hacke,et al.  Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. , 1999, Neurology.

[39]  H. Ellis stroke , 1997, The Lancet.

[40]  J T Hoff,et al.  Ischemic Brain Edema and the Osmotic Gradient between Blood and Brain , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.